GeneMedi's GMP-h-β-CTx-Ab01/02/03/04 (Anti-human β-CTx mouse monoclonal antibody) validation with GMP-h-β-CTx-Ag01 (Recombinant human β-CTx Protein)

Evidence has shown activated osteoclasts create resorption pits with low pH to dissolve the inorganic matrix and lysomal enzymes, such as TRAP and cathepsin K, effectively digest the exposed type-1 collagen releasing specific degradation products, such as the carboxyl-terminal cross-linked telopeptides of type I collagen (CTX-1). The biomarker β-CTx offers significant information on bone metabolism (bone remodeling) and is useful to predict fracture risk and to monitor the treatment efficacy. Recently, our R&D department demonstrated that our GMP-h-β-CTx-Ab pairs have a large linear range and good sensitivity against the GMP-h-β-CTx-Ag01. Below is the result of GeneMedi's GMP-h-β-CTx-Ab01/02/03/04 (Anti-human β-CTx mouse monoclonal antibody) validation with GMP-h-β-CTx-Ag01 (Recombinant human β-CTx Protein) in ELISA. We highly recommend the Ab01-Ab02 pair and Ag to you.

Figure 1. GeneMedi's GMP-h-β-CTx-Ab01/02/03/04 (Anti-human β-CTx mouse monoclonal antibody) are validated to detect the GMP-h-β-CTx-Ag01 (Recombinant human β-CTx Protein) in ELISA.

???EC50 [Ab01 (capture)-Ab02 (detect) ]= 271.3 ppb;

???EC50 [Ab01 (capture)-Ab04 (detect)]= 614.8 ppb;

???EC50 [Ab03 (capture)-Ab02 (detect) ]= 363.5 ppb;

???EC50 [Ab03 (capture)-Ab04 (detect) ]= 811.8 ppb.